Twirla Patch
NDC 71671-100
Product Information
Twirla (levonorgestrel/ethinyl estradiol) is a NDA-approved product labeled by Agile Therapeutics, Inc.. This medication is typically used as a estrogen receptor agonists [moa]. It is supplied as a patch for transdermal administration. This product entry covers the primary NDC 71671-100 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 71671-100?
What are the uses of this product?
What are Active Ingredients of this product?
- ETHINYL ESTRADIOL 2.3 mg/1 - A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
- LEVONORGESTREL 2.6 mg/1 - A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LEVONORGESTREL (UNII: 5W7SIA7YZW)
- LEVONORGESTREL (UNII: 5W7SIA7YZW) (Active Moiety)
- ETHINYL ESTRADIOL (UNII: 423D2T571U)
- ETHINYL ESTRADIOL (UNII: 423D2T571U) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ETHYL LACTATE (UNII: F3P750VW8I)
- CAPRIC ACID (UNII: 4G9EDB6V73)
- DIMETHYL SULFOXIDE (UNII: YOW8V9698H)
- LAURYL LACTATE (UNII: G5SU0BFK7O)
- POLYISOBUTYLENE (55000 MW) (UNII: TQ77WR8A02)
- POLYISOBUTYLENE (1100000 MW) (UNII: FLT10CH37X)
- COPOVIDONE K25-31 (UNII: D9C330MD8B)
- NITROGEN (UNII: N762921K75)
- HEPTANE (UNII: 456148SDMJ)
- POLYBUTENE (1400 MW) (UNII: 1NA5AO9GH7)
- CROSPOVIDONE (12 MPA.S AT 5%) (UNII: 40UAA97IT9)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2396242 - ethinyl estradiol 120 MCG / levonorgestrel 30 MCG per 24 HR Weekly Transdermal System
- RxCUI: 2396242 - 168 HR ethinyl estradiol 0.00125 MG/HR / levonorgestrel 0.005 MG/HR Transdermal System
- RxCUI: 2396253 - {3 (168 HR ethinyl estradiol 0.00125 MG/HR / levonorgestrel 0.005 MG/HR Transdermal System) } Pack
- RxCUI: 2396253 - ethinyl estradiol 120 MCG / levonorgestrel 30 MCG per 24 HR Weekly Transdermal System, 3 Count
- RxCUI: 2396258 - Twirla Weekly Replacement Transdermal System
Which are the Pharmacologic Classes of this product?
- Estrogen Receptor Agonists - [MoA] (Mechanism of Action)
- Estrogen - [EPC] (Established Pharmacologic Class)
- Inhibit Ovum Fertilization - [PE] (Physiologic Effect)
- Progesterone Congeners - [CS]
- Progestin - [EPC] (Established Pharmacologic Class)
- Progestin-containing Intrauterine System - [EPC] (Established Pharmacologic Class)
* Please review the full disclaimer at the bottom of this page.